HCI-013 breast cancer PDX
HCI-013 PDX: One of many Patient Derived Xenografts providing models for breast cancer including drug-resistant, metastatic tumours, and HER2+ tumours.
Contributors
| Inventor | Institute |
|---|---|
| Alana L Welm, Yi-Chun Lin, Yoko Sakata DeRose | The University of Utah Research Foundation |
| SKU: | 162081 |
|---|---|
| Product description: | HCI-013 PDX: One of many Patient Derived Xenografts providing models for breast cancer including drug-resistant, metastatic tumours, and HER2+ tumours. |
| Cat. #: | 162081 |
|---|---|
| Cancer types: | Breast cancer |
| Cancer Subtype: | Infiltrating Lobular Carcinoma |
| Gender: | Female |
| Cancer Stage or Grade: | Stage IV |
| Biopsy Site: | Pleural Effusion Fluid |
| Patient ethnicity: | Caucasian |
| Treatment History: | Pretreated: Patient had undergone radiation therapy to bone other than spine (2007) and spine (2010) and had systemic treatment of leuprolide 2003-2008; letrozole 2003-2007; zolendronic acid 2003-2010; tamoxifen 2007-2008; exemestane 2008; cyclophosphamide, 2008; 5-fluorouracil, methotrexate 2008; capecitabine 2008-2009; paclitaxel 2009; nab-paclitaxel 2009; doxorubicin 2009-2010; carboplatin, gemcitabine 2010 prior to sample collection |
| Primary citation: | Guillen, et al. 2022. Nature Cancer. Feb; 3(2):232-250. PMID: 35221336 |
| Initial handling information: | Implant into the cleared inguinal mammary fat pad of female Immune-compromised mice (NOD.SCID). Time to grow to 2cm: 3-6 months. Positive ER status |
|---|---|
| Additional notes: | Additional Information on PDX establishment: https://www.nature.com/articles/s43018-022-00337-6/figures/9 |
| Mice Passaged: | Yes |
|---|---|
| Engraftment Site: | Cleared mammary fat pad |
| Sample Type: | Suspension in Matrigel |
| Host Strain: | Immunocompromised mice NOD scid gamma (NSG) Jackson Laboratory 5557; NOD/scid, Jackson Laboratory 1303 or NOD rag gamma (NRG), Jackson Laboratory 7799 |
| Histology: | PAM50 subtype Luminal B |
| Production details: | Fresh or thawed human breast tumour fragments were implanted into the cleared inguinal mammary fat pad of female Immune-compromised mice. For bone metastasis samples, bone fragments were coimplanted. For liquid specimens, pleural effusion, or ascites fluid, 1-2 milion cells were injected into cleared mammary fat pads in Matrigel. For ER+ tumours, mice were dosed with E2 beeswax pellets and given supplemental E2 via drinking water. When tumours reached 1-2 cm in diameter, tumours were aseptically collected and reimplanted into new m ice or banked. Estrogen-independent ER+ breast PDX models were generated when ER+ PDX tumours were transplated into overiectomized mice without E2 supplementation. |
| References: |
Tufail, et al. 2024. Journal of Translational Med. Jan 3:22(1):15. PMID: 38172946 Bhattacharya, et al. 2023. Journal of Experimental & Clinical Cancer Research. Dec 16:42(1):343. PMID: 38102637 Prekovic, et al. 2023. EMBO Molecular Medicine. Dec 7:15(12):e17737. PMID: 37902007 Daneshdoust, et al. 2023. Cells. Sep 30:12(19):2338. PMID: 37830602 Wang, et al. 2023. Cell Bioscience. Dec 1:13(1):224. PMID: 38041134 Guillen, et al. 2022. Nature Cancer. Feb 3(2):232-250. PMID: 35221336 |
|---|
Powered by Bioz 
